Linked Data API

Show Search Form

Search Results

818607
registered interest false more like this
date less than 2018-01-08more like thisremove minimum value filter
answering body
Department of Health remove filter
answering dept id 17 more like this
answering dept short name Health more like this
answering dept sort name Health more like this
hansard heading Mefloquine more like this
house id 2 more like this
legislature
25277
pref label House of Lords more like this
question text To ask Her Majesty's Government, further to the Written Answer by Lord O'Shaughnessy on 22 December 2017 (HL4314), whether they consider suicide, as listed in the current mefloquine product information as a psychiatric adverse reaction, to be a permanent adverse reaction. more like this
tabling member printed
The Countess of Mar more like this
uin HL4484 remove filter
answer
answer
is ministerial correction false more like this
date of answer less than 2018-01-18more like thismore than 2018-01-18
answer text <p>Feeling suicidal, or the risk of suicide, would not be considered to be permanent adverse reactions.</p><p>Mefloquine is effective in the prevention and treatment of malaria and is approved by the Medicines and Healthcare products Regulatory Agency (MHRA), which regulates medication in the United Kingdom. As with all medicines, the MHRA keeps the safety of mefloquine under continual review. Mefloquine continues to be recommended as a safe and effective form of malaria prevention by the Advisory Committee on Malaria Prevention, the World Health Organization and other respected organisations who take account of the body of global evidence.</p> more like this
answering member printed Lord O'Shaughnessy more like this
question first answered
less than 2018-01-18T12:23:37.913Zmore like thismore than 2018-01-18T12:23:37.913Z
answering member
4545
label Biography information for Lord O'Shaughnessy more like this
tabling member
1861
label Biography information for The Countess of Mar more like this